A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 680 participants.

Also called NCT07913061

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 680 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07913061
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07913061. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
SHR-3167
Intervention (Drug)
insulin degludec
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07913061
Content hash
55e45dd7be45b04ef05d1ab22bfcaa4d03c927a2d07fe92177d73b3d8c76dd64